

MAY - 2 2012

SECTION 5  
510(k) SUMMARY

---

**510(k) SUMMARY**

**1. Submitter:**

Boston Scientific Corporation  
100 Boston Scientific Way  
Marlborough, MA 01752  
Telephone: 508-683-4560  
Fax: 508-683-5939

Contact: Janis F. Taranto, M.S., RAC  
Regulatory Affairs Specialist  
Date Prepared: March 30, 2012

**2. Proposed Device:**

Trade Name: Ultraflex™ Esophageal NG Stent System  
Classification Name: Esophageal Prosthesis  
Regulation Number: 878.3610  
Product Code: ESW  
Classification: Class II

**3. Predicate Device:**

Trade Name: Ultraflex™ Esophageal NG Stent System  
Manufacturer and Clearance Number: Boston Scientific Corporation, K091816  
Classification Name: Esophageal Prosthesis  
Regulation Number: 878.3610  
Product Code: ESW  
Classification: Class II

**4. Proposed Device Description:**

The proposed Ultraflex Esophageal NG Stent System allows for the placement of a self-expanding metallic stent within the esophagus. The systems consist of a flexible delivery catheter preloaded with an expandable stent. The stent is offered covered with either a proximal release or distal release delivery system. The stent may be placed fluoroscopically using radiopaque markers as a guide or endoscopically using the visual marker on the delivery catheter. The proposed device incorporates a material formulation change for the stent covering and covering adhesive material.

**5. Intended Use:**

Ultraflex™ Esophageal NG Stent System (covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors only, and occlusion of concurrent esophageal fistula.

**6. Technological Characteristics:**

The proposed Ultraflex™ Esophageal NG Stent System is identical in design and manufacturing processes to the predicate Ultraflex™ Esophageal NG Stent System (K091816) while incorporating a minor formulation change to the stent covering and covering adhesive material.

**7. Performance Data:**

*In-vitro* testing has been performed and all components, subassemblies, and/or full devices met the required specifications for the completed tests including: dimensional, tensile strength, integrity, exposure resistance, chemical analysis and biocompatibility.

**8. Conclusion:**

Boston Scientific Corporation has demonstrated that the proposed Ultraflex™ Esophageal NG Stent System is substantially equivalent to Boston Scientific Corporation's currently marketed Ultraflex™ Esophageal NG Stent System (K091816).



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room – WO66-G609  
Silver Spring, MD 20993-0002

MAY 2 2012

Ms. Janis F. Taranto, M.S., RAC  
Regulatory Affairs Specialist  
Boston Scientific Corporation  
100 Boston Scientific Way, M-11  
MARLBOROUGH MA 01752

Re: K120983  
Trade/Device Name: Ultraflex™ Esophageal NG Stent System  
Regulation Number: 21 CFR§ 878.3610  
Regulation Name: Esophageal prosthesis  
Regulatory Class: II  
Product Code: ESW  
Dated: March 30, 2012  
Received: April 2, 2012

Dear Ms. Taranto:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Benjamin R. Fisher, Ph.D.

Director

Division of Reproductive, Gastro-Renal,  
and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

SECTION 4  
INDICATIONS FOR USE STATEMENT

---

510(k) Number (if known): ~~To Be Determined~~ K120983

Device Name: Ultraflex™ Esophageal NG Stent System

Indications for Use: Ultraflex™ Esophageal NG Stent System (covered) is intended for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and/or extrinsic malignant tumors only, and occlusion of concurrent esophageal fistula.

Prescription Use  X   
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of Reproductive, Gastro-Renal, and  
Urological Devices  
510(k) Number  K120983